Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102629 | 0.93 | ITGB1 (0.57) | ITGB1ITGA4 | |
| SCHEMBL7102625 | 0.93 | ITGB1 (0.57) | ITGB1ITGA4 | |
| SCHEMBL7098724 | 0.88 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL7098727 | 0.88 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL7105450 | 0.87 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL7102026 | 0.87 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL7102405 | 0.86 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL7098631 | 0.86 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL7102736 | 0.86 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL7102743 | 0.86 | ITGB1 (0.61) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGB1 3/4885ITGA4 8/4885CYP1A2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.